Jasper Therapeutics Inc expected to post a loss of $1.07 a share - Earnings Preview

Jasper Therapeutics

06/11/2024 14:14

* Jasper Therapeutics Inc  JSPR.OQ   JSPR.O  is expected
to show
no change in quarterly revenue when it reports  results on
November 7 (estimated) for the period ending September 30 2024
    * 
    * ​LSEG's mean analyst estimate for Jasper Therapeutics Inc
is for
a loss of $1.07 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Jasper
Therapeutics Inc is $70.00​, above​ its last closing price
of $22.40. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -1.08       -1.09      -0.97     Beat    10.9
 Mar. 31 0001  -1.23       -1.22      -1.03     Beat    15.9
 Dec. 31 2023  -1.60       -1.61      -1.50     Beat    7.1​
 Jan. 1 0001   -1.53       -1.55      -1.60     Missed  -3.1
 ​​Jun.        -1.81       -1.50      -1.50     Met     -0.1
 30 2023                                                
 Mar. 31 2023  -1.64       -1.62      -1.60     Beat    1.5​
 Jan. 1 0001   -3.51       -3.60      -3.60     Met     0
 Jan. 1 0001   -3.40       -3.42      -3.20     Beat    6.6
 This summary was machine generated November 6 at 14:14 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)